• A
  • A
Font Size

Resources for eye conditions

The following organizations offer information and resources on living with eye conditions that can affect vision:

  • Foundation Fighting Blindness
    Dedicated to funding innovative research to find preventions, treatments, and cures for inherited retinal degenerative diseases. 1-800-683-5555
  • Lighthouse Guild
    The leading not-for-profit vision and healthcare organization with a long-standing heritage of addressing the needs of people who are blind or visually impaired. 1-800-284-4422
  • Prevent Blindness
    Leading consumer advocate for eye health and safety with the mission of preserving sight. 1-800-331-2020
  • VisionAware
    Helps adults who are losing their sight by providing information, daily living techniques, a directory of services, and a supportive online community.

While Regeneron Pharmaceuticals does provide financial support to patient support organizations, Regeneron does not endorse any specific patient organization. The information provided by Regeneron or these organizations is meant for informational purposes only and is not meant to replace a physician's medical advice.

Need a ride? Rides in Sight can help

Sometimes getting to and from your eye care appointments can be difficult. Regeneron Pharmaceuticals, the maker of EYLEA, supports Rides in Sight,* a transportation-referral service.

Want to see if this service is available near you?

Learn more about Rides In Sight

Or call 1-855-607-4337

*Rides in Sight is not affiliated or related to EYLEA, EYLEA4U®, or Regeneron. Regeneron does not influence or control the operations of Rides in Sight and cannot guarantee assistance will be provided. Rides in Sight is not an emergency service. If you have an emergency, call 9-1-1.


Resources for Wet AMD

The following organizations offer information on living with Wet AMD:

  • AMD Alliance International
    Strives to bring knowledge, help, and hope to individuals and families around the world affected by AMD. 1-800-829-0500
  • BrightFocus Foundation
    Funds research and educates the public about macular degeneration and other conditions. 1-800-437-2423
  • Macular Degeneration Support
    Offers information and personal assistance for people dealing with macular degeneration and similar eye conditions. 1-888-866-6148
  • Macular Degeneration Partnership
    Provides comprehensive information about AMD and supports ongoing research into new treatments. 1-888-430-9898
  • National Eye Institute: AMD
    Dedicated to vision research that saves sight and reduces visual impairment and blindness. 1-301-496-5248
  • VisionAware
    Helps adults who are losing their sight by providing information, daily living techniques, a directory of services, and a supportive online community.


Support from EYLEA4U

EYLEA4U is a comprehensive support program with several resources available to help eligible patients with the cost of EYLEA, whether insured by private health insurance, insurance through a government program (like Medicare), or no insurance at all. You or your doctor's office can help you get started by calling 1-855-EYLEA4U (1-855-395-3248) Monday through Friday 9 AM to 8 PM Eastern Time.

Sign up for more information

Get the latest materials and communications about EYLEA – and a complimentary pocket magnifier, too.

Important Safety Information
  • EYLEA® (aflibercept) Injection is a prescription medication administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
Top
Important Safety Information
  • EYLEA® (aflibercept) Injection is a prescription medication administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
  • Injection into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye). Inflammation in the eye has been reported with the use of EYLEA.
  • In some patients, injections with EYLEA may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.
  • There is a potential risk of serious and sometimes fatal side effects related to blood clots, leading to heart attack or stroke in patients receiving EYLEA.
  • Serious side effects related to the injection procedure with EYLEA are rare but can occur including infection inside the eye and retinal detachment.
  • The most common side effects reported in patients receiving EYLEA are increased redness in the eye, eye pain, cataract, moving spots in the field of vision, increased pressure in the eye, and vitreous (gel-like substance) detachment.
  • It is important that you contact your doctor right away if you think you might be experiencing any side effects, including eye pain or redness, light sensitivity, or blurring of vision, after an injection.
  • EYLEA is for prescription use only. For additional safety information, please talk to your doctor and see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indications

EYLEA® (aflibercept) Injection is a prescription medicine approved for the treatment of patients with:

  • Wet Age-related Macular Degeneration (AMD): The recommended dose for EYLEA is 2 mg administered by injection in the eye every 2 months (8 weeks) following 3 initial monthly (every 4 weeks) injections. EYLEA may be dosed once per month, but in most patients, additional benefit was not seen with this dosing plan. Some patients may need monthly (every 4 weeks) dosing after the first 3 months (12 weeks).
  • Macular Edema following Retinal Vein Occlusion (RVO): The recommended dose for EYLEA is 2 mg administered by injection in the eye monthly (every 4 weeks).
  • Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR) in patients with DME: The recommended dose for EYLEA is 2 mg administered by injection in the eye every 2 months (8 weeks) following 5 initial monthly (every 4 weeks) injections. EYLEA may be dosed once per month, but in most patients, additional benefit was not seen with this dosing plan. Some patients may need monthly (every 4 weeks) dosing after the first 5 months (20 weeks).
Please see the full Prescribing Information for EYLEA.

The information contained herein is provided for general educational purposes. If you have any questions, talk to your doctor.